CA3174377A1 - Compositions comprising recombinant epo and methods of use thereof - Google Patents

Compositions comprising recombinant epo and methods of use thereof Download PDF

Info

Publication number
CA3174377A1
CA3174377A1 CA3174377A CA3174377A CA3174377A1 CA 3174377 A1 CA3174377 A1 CA 3174377A1 CA 3174377 A CA3174377 A CA 3174377A CA 3174377 A CA3174377 A CA 3174377A CA 3174377 A1 CA3174377 A1 CA 3174377A1
Authority
CA
Canada
Prior art keywords
polypeptide
subject
administering
effective amount
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3174377A
Other languages
English (en)
French (fr)
Inventor
Samuel Newton Sathyanesan
Monica SATHYANESAN
Jason PETERSEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of South Dakota
United States Department of Veterans Affairs
Original Assignee
United States Department of Veterans Affairs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United States Department of Veterans Affairs filed Critical United States Department of Veterans Affairs
Publication of CA3174377A1 publication Critical patent/CA3174377A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA3174377A 2020-04-09 2021-04-09 Compositions comprising recombinant epo and methods of use thereof Pending CA3174377A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063007716P 2020-04-09 2020-04-09
US63/007,716 2020-04-09
PCT/US2021/026593 WO2021207611A1 (en) 2020-04-09 2021-04-09 Compositions comprising recombinant epo and methods of use thereof

Publications (1)

Publication Number Publication Date
CA3174377A1 true CA3174377A1 (en) 2021-10-14

Family

ID=78023216

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3174377A Pending CA3174377A1 (en) 2020-04-09 2021-04-09 Compositions comprising recombinant epo and methods of use thereof

Country Status (4)

Country Link
US (1) US20230151071A1 (de)
EP (1) EP4132958A4 (de)
CA (1) CA3174377A1 (de)
WO (1) WO2021207611A1 (de)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1088084T3 (da) * 1998-06-15 2007-01-29 Gtc Biotherapeutics Inc Erythropoietin analog-humant serumalbumin fusionsprotein
JP2002531089A (ja) * 1998-11-30 2002-09-24 イーライ・リリー・アンド・カンパニー 赤血球産生性化合物
WO2004022593A2 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
GB0602173D0 (en) * 2006-02-03 2006-03-15 Avecia Ltd Expression system
WO2008065372A2 (en) * 2006-11-28 2008-06-05 Nautilus Biotech, S.A. Modified erythropoietin polypeptides and uses thereof for treatment
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
WO2009152944A1 (en) * 2008-05-29 2009-12-23 Hanall Pharmaceutical Co., Ltd Modified erythropoietin (epo)polypeptides that exhibit increased protease resistance and pharmaceutical compositions thereof
KR101364864B1 (ko) * 2012-01-30 2014-02-20 울산대학교 산학협력단 인간 적혈구 형성 자극인자 발현 벡터 및 이를 이용한 인간 적혈구 형성 자극인자의 생산방법

Also Published As

Publication number Publication date
WO2021207611A1 (en) 2021-10-14
WO2021207611A9 (en) 2021-12-30
US20230151071A1 (en) 2023-05-18
EP4132958A4 (de) 2024-05-15
EP4132958A1 (de) 2023-02-15

Similar Documents

Publication Publication Date Title
CN109715658B (zh) 可溶性成纤维细胞生长因子受体3(sfgfr3)多肽及其用途
WO2005021758A1 (en) Recombinant polypeptide useful for neurotrophin receptor mediated gene delivery and as neurotrophin agonist
EP3493829B1 (de) Zusammensetzungen und verfahren zur schlaganfallvorbeugung in pädiatrischen patienten mit sichelzellanämie
CA3156506A1 (en) Recombinant cdkl5 proteins, gene therapy and production methods
CN111349154A (zh) 一种重组人促卵泡激素及其制备方法和药物应用
CN101175768B (zh) 促红细胞生成素变体
WO2014093251A1 (en) Engineered receptors and their use
US20230151071A1 (en) Compositions comprising recombinant epo and methods of use thereof
US10385113B2 (en) Engineered FGF compositions and methods of use thereof
US20090069230A1 (en) Gdnf-derived peptides
US9469679B2 (en) Neurturin molecules
AU2009265327A1 (en) Insulin fusion polypeptides
JP2009504689A (ja) Ｇｄｎｆ由来ペプチド
AU2020370362A1 (en) Computational design of alpha(v) beta (6) integrin binding proteins
CN113747903A (zh) 胶质母细胞瘤干细胞的核心主调节子
US20110312883A1 (en) Neurturin molecules
US20230055021A1 (en) Methods for treating psychiatric disorders or symptoms thereof using ncam peptide mimetics
EP2774935A1 (de) Verbesserte Neurturinmoleküle
WO2007023479A2 (en) Treatment of central nervous system injury
WO2024149277A1 (en) Polymeric immunoglobulin receptor mutants and uses thereof
JP2010520761A5 (de)
WO2024229964A1 (zh) 细胞外囊泡支架蛋白及其应用
WO2025083294A2 (en) Aat-fc fusion protein
CA3208936A1 (en) Retroviral vectors
WO2022072550A2 (en) Clec2 fusion protein and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220930

N11 Application terminated

Free format text: ST27 STATUS EVENT CODE: T-6-6-N10-N11-N106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION NOT REINSTATED BY DEADLINE

Effective date: 20250626

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250924

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251124

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: T-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260521